Actavis has a broad product portfolio and strong pipeline.
Our Research and Development (R&D) strategy for our generic products focuses on the following product development areas:
Off-patent drugs that are difficult to develop or manufacture, or that complement or broaden our existing product lines;
Patent challenge products where the company believes either the brand patent is invalid or its product does not infringe; and
The development of sustained-release, semi-solid, liquid, oral transmucosal, transdermal, gel, injectable, inhalation and other drug delivery technologies and the application of these technologies to proprietary drug forms.